NANO Nuclear Energy (NNE) shares are surging higher again today as the stock crosses above a psychologically significant price.
Earlier this week, the announcement that NANO Nuclear Energy would be included in the Russell 3000 “Total Market” Index sparked buying interest in the developmental company.
Nano is a nuclear energy and technology company focused on developing portable, clean energy solutions. Investors and analyst have speculated that the company could develop solutions for the historic increase for energy demand associated with AI technology.
Nano Nuclear Energy shares traded as high as $35 in May on the public’s initial interest and speculation. Since then, shares declined to their August lows near $6 before headlines and analyst comments attracted buyers back to the name.
On Wednesday, shares of NNE crossed above $10, a significant psychological price point for any stock. Moving above $10 also attracts institutional buyers.
The stock will now target a move to $15, which would cross above its 50-day moving average. That move would put the stock back in an intermediate-term bull market trend with a price target of $25.
Moderna's (MRNA) stock traded more than 20% lower today after the company announced significant cuts in its research and development (R&D) budget.
The budget cuts were part of the company’s outlook for 2025, which included lowering growth and revenue expectations for the upcoming fiscal year.
Moderna has struggled to diversify the company’s offerings beyond its COVID-19 vaccine revenue stream which has been the primary revenue driver since the 2020 Pandemic.
Moderna stock has been trading in a long-term bear market trend since January 2022 when shares broke below their 20-month moving average. Ince then, the stock has lost 63% of their value. Shares currently trade 83% below their 2021 all-time highs of $500 per share.
From a shorter-term perspective, Moderna shares are trapped in an intermediate-term bear market trend, now breaking through significant price support.
Shares are breaking through the $80 and $70 price today, a price that has served as short-term support. Today’s break through $70 is on significantly higher volume, indicating that selling pressure is likely to continue.
Shares of Moderna remain in a long-term bear market with a price target of $50.
Shares of McDonald’s (MCD) are struggling to break higher today, despite news that the fast food restaurant will continue offering their $5 Value Meals through December.
In July, McDonald’s became more aggressive with their menu pricing, working with franchise owners to increase their lower-priced menu offerings. The move was in response to lower revenue caused by McDonald’s customers spending adjustments after more than two years of inflationary price pressure.
Since July, McDonald’s shares have added more than 20% from as initial results from the push to provide lower menu pricing has resulted in increased traffic and revenue at the franchise level.
Shares have been trading in a tight range between $285 and $295 with positive momentum preparing to shift the stock above round-numbered resistance at $300.
In mid-August, the stock’s 50-day moving average shifted into a bullish trend. That same trendline is preparing to cross above the 200-day moving average, resulting in a Golden Cross pattern that would forecast higher prices over the next 4-6 months.
The move above $300 would strike new all-time highs for shares of McDonald’s, luring more investors into the long-term bullish outlook for the stock.
Shares of McDonald’s maintain a bullish outlook with a target price of $400.
